跳至主要内容
临床试验/NL-OMON32708
NL-OMON32708尚未招募不适用

31P Magnetic Resonance Spectroscopic Imaging of brain tumours - 31P MRSI of brain tumours

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • patients with a glial tumour and without MRI contra-indication

排除标准

  • patients with MRI contra-indication. patients that are claustrofobic. Patients with pacemakers or neurostimulators. Patients with large metal implants

研究者

发起方
niversitair Medisch Centrum Sint Radboud

相似试验

已完成
不适用
Insomnia Magnetic Resonance Spectroscopy (MRS) imaging sleep study
ACTRN12612000050853niversity of Sydney47
终止
不适用
This research study will use Magnetic Resonance Imaging (MRI) techniques to learn whether hearing aids do have an effect on cognitive function and the brain of older adults with hearing loss.Hearing lossDepression
ACTRN12617001616369Professor Denny Meyer25
已完成
2 期
A Magnetic Resonance Spectroscopy (MRS) study to explore the effects of a medical food on brain metabolites in patients with mild Alzheimer's Disease dementia(AD)10029305dementiaAlzheimer's Disease
NL-OMON39865utricia Research30
进行中(未招募)
不适用
A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not appilcableThe purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple sclerosis (RRMS).
EUCTR2004-002567-24-CZMillennium Pharmaceuticals, Inc.160
进行中(未招募)
不适用
A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not applicableThe purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple sclerosis (RRMS).
EUCTR2004-002567-24-HUMillennium Pharmaceuticals, Inc.160